On Monday, the U.S. Food and Drug Administration (FDA) approved Abbott Laboratories’ (NYSE: ABT) Volt PFA System to treat patients battling atrial fibrillation (AFib). AFib is the most common type of ...
The Volt PFA system. [Image courtesy of Abbott] Abbott (NYSE: ABT) + announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib. Abbott said it plans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback